Advantage Investment Management’s Lam Research LRCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$214K Sell
9,240
-540
-6% -$11.3K 0.17% 139
2019
Q2
$184K Sell
9,780
-30
-0.3% -$569 0.14% 156
2019
Q1
$176K Sell
9,810
-340
-3% -$5.67K 0.14% 158
2018
Q4
$138K Buy
10,150
+2,330
+30% +$33.4K 0.1% 188
2018
Q3
$119K Buy
7,820
+3,110
+66% +$53.1K 0.08% 242
2018
Q2
$81K Hold
4,710
0.06% 288
2018
Q1
$96K Hold
4,710
0.04% 259
2017
Q4
$87K Hold
4,710
0.03% 314
2017
Q3
$87K Hold
4,710
0.03% 282
2017
Q2
$67K Buy
4,710
+420
+10% +$6.16K 0.02% 301
2017
Q1
$55K Hold
4,290
0.02% 321
2016
Q4
$45K Hold
4,290
0.02% 348
2016
Q3
$41K Hold
4,290
0.02% 360
2016
Q2
$36K Buy
4,290
+2,000
+87% +$16.1K 0.02% 387
2016
Q1
$19K Buy
2,290
+2,000
+690% +$14.5K 0.01% 473
2015
Q4
$2K Hold
290
﹤0.01% 775
2015
Q3
$2K Hold
290
﹤0.01% 751
2015
Q2
$2K Hold
290
﹤0.01% 781
2015
Q1
$2K Hold
290
﹤0.01% 781
2014
Q4
$2K Buy
+290
New +$2.25K ﹤0.01% 708

Other funds holding LRCX

Advantage Investment Management's LRCX Position: Q3 2019 in Review

Advantage Investment Management reduced its Lam Research (LRCX) stake by 5.5% in Q3 2019, selling an estimated $11.3K and leaving 9,240 shares worth $214K. The position accounts for 0.17% of the portfolio, ranked #139.

Advantage Investment Management first reported a position in LRCX in Q4 2014 and has held it in 20 quarters since. 881 funds tracked by Wall St. Rank hold LRCX as of Q3 2019.

  • Advantage Investment Management held 9,240 shares of Lam Research worth $214K as of Q3 2019.
  • Advantage Investment Management sold 540 Lam Research shares in Q3 2019, an estimated $11.3K.
  • Lam Research made up 0.17% of Advantage Investment Management's portfolio in Q3 2019, its #139 holding.
  • Advantage Investment Management first reported a position in Lam Research in Q4 2014 and has held it in 20 quarters since.
  • 881 funds tracked by Wall St. Rank held Lam Research as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.